HD-OPM Archive
Topics › Aspirin, antiplatelets & blood thinners

ASPREE sub-analysis: aspirin tied to ~70% lower dementia in a platelet-genetics subgroup

Louis Nervegna · Oct 05, 2026 · ♥ 1 reactions · 0 comments · original Facebook post
Aspirin, antiplatelets & blood thinnersBrain health & dementia
AI summary & key facts

A genetic analysis of 13,541 ASPREE participants found aspirin did not prevent dementia overall, but in the top 20% of a platelet-count genetic score dementia occurred in about 1% on aspirin versus 3.3% on placebo. Major bleeding was more than twice as common in this subgroup, so the post cautions against starting aspirin for dementia prevention.

#aspirinHD #aspreeHD #dementiaHD #alzheimersHD #plateletsHD #apoe4HD

Research cited

💊 Daily low-dose aspirin was linked to a dramatically lower risk of dementia in a specific genetic subgroup of older adults.

Researchers analysed genetic data from 13,541 participants in the large ASPREE randomized trial, which originally tested daily aspirin against placebo in healthy older adults.

When everyone in the trial was considered together, aspirin did not prevent dementia.

But researchers wondered whether genetics might reveal people who respond differently.

They calculated thousands of genetic risk scores and found one particularly interesting signal linked to platelet count — the number of blood cells involved in clotting.

Among participants in the highest 20% for this platelet-related genetic score, dementia developed in about 3.3% of people taking placebo.

Among those assigned to aspirin, only about 1% developed dementia.

That corresponds to roughly a 70% lower relative risk.

The difference began to emerge around two to three years after treatment started.

Interestingly, the effect was not linked to well-known Alzheimer’s risk genes such as APOE.

Instead, it points toward platelet biology, raising the possibility that blood clotting and vascular processes may influence dementia risk in certain people.

But there was an important downside.

Major bleeding occurred in 4.4% of aspirin users in this genetic subgroup, compared with 2.1% of those taking placebo — more than twice as often.

This means people should not start taking aspirin to prevent dementia based on this result.

The finding came from a secondary genetic analysis rather than a trial specifically designed to test genetically targeted dementia prevention.

It also combined different forms of dementia and followed participants for less than five years on average.

Still, if confirmed, the study suggests genetics could one day help identify people for whom a cheap, widely available medicine offers more benefit than harm.

📃 RESEARCH PAPER
📌 Fransquet et al., “Platelet count polygenic scores may modify the effect of aspirin in primary prevention of dementia”, Alzheimer’s & Dementia (2026)

May be an image of drink and text
← newer: Pooled analysis of 68,000 people: higher blood linoleic acidolder: Transplanted hearts take on the biological age of their reci →